Quick Answer
Voyager Therapeutics, Inc. reported Operating Income of -$131.84 million for fiscal year 2025.
Voyager Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$131.84M | -58.3% |
| 2024 | -$83.29M | -168.3% |
| 2023 | $122.01M | +340.0% |
| 2022 | -$50.84M | +30.9% |
| 2021 | -$73.62M | -368.8% |
| 2020 | $27.38M | +153.0% |
| 2019 | -$51.68M | +43.3% |
| 2018 | -$91.09M | -26.8% |
| 2017 | -$71.86M | -74.0% |
| 2016 | -$41.30M | -103.9% |
| 2015 | -$20.25M | -41.0% |
| 2014 | -$14.37M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$30.59M | -122.0% | +16.5% |
| June 30, 2025 | -$36.62M | -143.8% | -5.6% |
| March 31, 2025 | -$34.69M | -114.4% | -151.8% |
| September 30, 2024 | -$13.78M | +53.3% | +8.3% |
| June 30, 2024 | -$15.03M | +40.9% | +7.2% |
| March 31, 2024 | -$16.18M | -113.2% | +45.2% |
| September 30, 2023 | -$29.51M | -304.3% | -16.1% |
| June 30, 2023 | -$25.43M | -31.3% | -120.7% |
- Voyager Therapeutics, Inc. showed a decrease of -58.3% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Voyager Therapeutics, Inc.’s operating income has declined by 817.7% (from -$14.37 million to -$131.84 million).
- The most recent figure is from Voyager Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: